These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8210640)

  • 1. Interleukin-2-based immunotherapy in the management of minimal residual disease in acute leukemia patients.
    Foa R; Meloni G; Guarini A; Vignetti M; Marchis D; Tosti S; Gillio Tos A; Mandelli F; Gavosto F
    Recent Results Cancer Res; 1993; 131():207-14. PubMed ID: 8210640
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
    Benyunes MC; Thompson JA; York A; Buckner CD; Fefer A
    Prog Clin Biol Res; 1994; 389():229-38. PubMed ID: 7700905
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
    Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Guarini A; Cardona S; Gillio Tos A; Gavosto F; Mandelli F
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():98-102. PubMed ID: 2202476
    [No Abstract]   [Full Text] [Related]  

  • 4. Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies.
    Klingemann HG
    Leuk Lymphoma; 1992 Dec; 8(6):421-9. PubMed ID: 1284296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of human leukemia cells to allogeneic and autologous lymphokine-activated killer cells and its augmentation by exposure of leukemia target cells to cytotoxic drugs in vitro and in vivo.
    Teichmann JV; Ludwig WD; Thiel E
    Recent Results Cancer Res; 1993; 131():223-38. PubMed ID: 8210642
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.
    Fefer A; Benyunes MC; Massumoto C; Higuchi C; York A; Buckner CD; Thompson JA
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):41-5. PubMed ID: 8284691
    [No Abstract]   [Full Text] [Related]  

  • 8. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
    Dickinson AM; Lennard AL; Cartner R; Proctor SJ
    Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of interferon-gamma in the immunotherapy of neuroblastoma.
    Handgretinger R; Bruchelt G; Daurer B; Lang P; Herter M; Dopfer R; Müller B; Reisfeld RA; Treuner J; Niethammer D
    Prog Clin Biol Res; 1991; 366():401-7. PubMed ID: 1906184
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dynamics of cytotoxicity of blood mononuclear cells in patients with bladder cancer during endolymphatic immunotherapy with lymphokine- activated killer cells and recombinant interleukin-2].
    Malakhova NV; Figurin KM; Fedorova NS; Kiselevskiĭ MV; Bykovskaia SN
    Biull Eksp Biol Med; 1996 Feb; 121(2):188-91. PubMed ID: 9026128
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 14. [The role of interleukin-2--based immunotherapy in hematological malignancies].
    Ackerstein A; Toren A; Slavin S; Nagler A
    Harefuah; 1996 May; 130(9):613-7. PubMed ID: 8794642
    [No Abstract]   [Full Text] [Related]  

  • 15. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract]   [Full Text] [Related]  

  • 16. Lymphokine activated killer cells: a new approach to immunotherapy of cancer.
    Semenzato G
    Leukemia; 1990 Feb; 4(2):71-80. PubMed ID: 2406518
    [No Abstract]   [Full Text] [Related]  

  • 17. Has IL2 a role in the management of minimal residual disease for acute leukemia?
    Foa R; Meloni G; Guarini A; Mandelli F; Gavosto F
    Leukemia; 1992 Nov; 6 Suppl 4():92-4. PubMed ID: 1434844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
    Blacklock JB; Grimm EA
    Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
    Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
    Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local and regional immunotherapy of cancer with interleukin 2.
    Bubeník J
    J Cancer Res Clin Oncol; 1990; 116(1):1-7. PubMed ID: 2179226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.